Home » Stocks » ACHV

Achieve Life Sciences, Inc. (ACHV)

Stock Price: $9.93 USD -0.30 (-2.93%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $9.89 -0.04 (-0.40%) Apr 16, 6:48 PM
Market Cap 61.07M
Revenue (ttm) n/a
Net Income (ttm) -14.73M
Shares Out 2.72M
EPS (ttm) -5.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $9.93
Previous Close $10.23
Change ($) -0.30
Change (%) -2.93%
Day's Open 10.35
Day's Range 9.64 - 10.49
Day's Volume 134,926
52-Week Range 6.60 - 18.26

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo Phase 3 ORCA-2 Trial Currently Enrolling at 16 sites in United States SEATTLE, WA and VANCOUVER, BC / ACCES...

5 days ago - Accesswire

Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline SEATTLE, WA and VANCOUVER...

3 weeks ago - Accesswire

Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 16, 2021 / Achieve Life Sci...

1 month ago - Accesswire

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization...

1 month ago - Accesswire

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization...

1 month ago - Accesswire

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization ...

1 month ago - Accesswire

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializatio...

3 months ago - Accesswire

SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...

4 months ago - PRNewsWire

SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...

4 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of ...

4 months ago - PRNewsWire

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

SEATTLE and VANCOUVER, BC, Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of ...

5 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of c...

5 months ago - PRNewsWire

SEATTLE and VANCOUVER, B.C., Oct. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...

6 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of...

7 months ago - PRNewsWire

SEATTLE, and VANCOUVER, British Columbia, Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and comme...

7 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, Sept. 10, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

7 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, Sept. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

7 months ago - PRNewsWire

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

SEATTLE and VANCOUVER, British Columbia, Aug. 6, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

8 months ago - PRNewsWire

SEATTLE and VANCOUVER, British Columbia, July 31, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerc...

8 months ago - PRNewsWire

SEATTLE and VANCOUVER, British Columbia, July 28, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerc...

8 months ago - PRNewsWire

SEATTLE and VANCOUVER, BC, June 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of ...

9 months ago - PRNewsWire

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SEATTLE and VANCOUVER, British Columbia, May 14, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerci...

11 months ago - PRNewsWire

Achieve Life Sciences, Inc.'s (ACHV) CEO Richard Stewart on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV) traded sharply higher Friday morning before paring those gains.

1 year ago - Benzinga

Achieve Life Sciences Inc a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation.

1 year ago - Benzinga

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Industry
Biotechnology
CEO
Richard Stewart
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
ACHV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACHV stock is "Buy." The 12-month stock price forecast is 45.20, which is an increase of 355.19% from the latest price.

Price Target
$45.20
(355.19% upside)
Analyst Consensus: Buy